In addition to high tumor T-cell infiltration, “immunologically hot” tumors that respond well to immunotherapy-based treatment typically express IFN-I (IFN-α, -β), type II interferons (IFN-II) (IFN-γ), and high levels of interferon-stimulated genes (ISGs) that sustain antitumor immune responses (Gajewski et al., 2013; Corrales et al., 2015; Wang and Wang, 2017). The gene discussed is IFNG; the disease is neoplasm.